Maze Q1 net loss $24.2M; MZE829 reduces proteinuria 35.6% in Phase 2 AMKD trial

Maze Therapeutics, Inc.

2026-Q1 EPS reported -$0.45 revenue$20,000,000

MZE829 Phase 2 HORIZON: 35.6% mean uACR reduction at week 12 in broad AMKD; 50% of patients had >30% reduction; no serious AEs.
In severe FSGS subgroup, MZE829 achieved 61.8% mean uACR reduction; in non-diabetic AMKD, 48.6% reduction.
Cash $362.9M at March 31, 2026; April 2026 raised ~$150M in offering plus $20M milestone from Shionogi; runway into 2029.
Net loss $24.2M ($0.45/share) vs $32.8M ($1.15) YoY; license revenue $20M; R&D $34.1M, G&A $12.4M.
MZE782 Phase 2 in PKU to start mid-2026 with topline data in 2027; Phase 2 in CKD expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Maze Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $20.0 million, net income $24.2 million, EPS $0.45 per share.

Period: first quarter ended March 31, 2026
Revenue: $20.0 million
Net income: $24.2 million
EPS: $0.45 per share
Result: reported results

Exact text from the filing

License Revenue: License revenue was $20.0 million for the quarter ended March 31, 2026. No license revenue was recognized for the quarter ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Maze Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.